Fractyl Health (GUTS) Expected to Announce Earnings on Tuesday

Fractyl Health (NASDAQ:GUTS) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.34. On average, analysts expect Fractyl Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fractyl Health Price Performance

Shares of GUTS stock traded down $0.04 during trading hours on Tuesday, reaching $0.69. The company’s stock had a trading volume of 1,130,567 shares, compared to its average volume of 4,537,396. The firm’s 50 day simple moving average is $0.50 and its 200-day simple moving average is $1.16. The company has a market capitalization of $109.63 million, a price-to-earnings ratio of -0.37 and a beta of 2.11. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 3.23.

Analyst Upgrades and Downgrades

GUTS has been the topic of a number of research analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Morgan Stanley downgraded Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Friday, April 24th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.40.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in shares of Fractyl Health by 23.5% during the 3rd quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after acquiring an additional 16,856 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Fractyl Health during the 2nd quarter valued at $31,000. Jump Financial LLC bought a new position in Fractyl Health during the 4th quarter worth $57,000. Scientech Research LLC bought a new position in Fractyl Health during the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC bought a new position in Fractyl Health during the 3rd quarter worth $55,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.